<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-575</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ И НАНОТЕХНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY AND NANOTECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>СИНТЕЗ РАДИОФАРМАЦЕВТИЧЕСКОГО ЛЕКАРСТВЕННОГО ПРЕПАРАТА, МЕЧЕННОГО РЕНИЕМ-188 И СОДЕРЖАЩЕГО ЛИПИОДОЛ</article-title><trans-title-group xml:lang="en"><trans-title>SYNTHESIS OF RADIOPHARMACEUTICAL WITH RHENIUM-188 AND LIPIODOL</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кодина</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kodina</surname><given-names>G. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малышева</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Malysheva</surname><given-names>A. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таратоненкова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Taratonenkova</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лямцева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyamtseva</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Константинов</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Konstantinov</surname><given-names>N. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Государственный научный центр Российской Федерации - Федеральный медицинский биофизический центр имени А.И. Бурназяна» (ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России)</institution></aff><aff xml:lang="en"><institution>A.I. Burnasyan Federal Medical Biophysical Center FMBA of Russia</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>2</issue><fpage>38</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кодина Г.Е., Малышева А.О., Таратоненкова Н.А., Лямцева Е.А., Константинов Н.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Кодина Г.Е., Малышева А.О., Таратоненкова Н.А., Лямцева Е.А., Константинов Н.А.</copyright-holder><copyright-holder xml:lang="en">Kodina G.E., Malysheva A.O., Taratonenkova N.A., Lyamtseva E.A., Konstantinov N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/575">https://www.pharmjournal.ru/jour/article/view/575</self-uri><abstract><p>Радиофармацевтический лекарственный препарат, меченный рением-188 и содержащий липиодол, синтезируют в медицинских организациях из набора реагентов и элюата из генератора ¹⁸⁸W/¹⁸⁸Re. Набор реагентов состоит из трех флаконов: лиофилизированного реагента № 1, содержащего олова дихлорид, лиофилизированного реагента № 2, содержащего натрия дитиобензоат, и раствора липиодола. Была разработана технология получения лиофилизированного реагента, содержащего олова дихлорид. Перед синтезом радиофармацевтического лекарственного препарата (РФЛП) проводили контроль качества раствора натрия перрената, ¹⁸⁸Re, получаемого из генератора (элюат). Результаты контроля качества РФЛП, полученного с использованием лиофилизированного реагента № 1 отечественного и импортного производства, показали их идентичность по показателю «радиохимическая чистота».</p></abstract><trans-abstract xml:lang="en"><p>Radiopharmaceutical with rhenium-188 and lypiodol is synthesized in medical organizations from a kit of reagents and eluate from the 188W/188Re generator. The kit of reagents consists of three vials: lyophilized reagent N 1 containing tin dichloride, lyophilized reagent N 2 - sodium dithiobenzoate, and reagent N 3 - lipiodol. A domestic technology was developed for obtaining a lyophilized reagent containing tin dichloride. Quality control of the sodium perrhenate, 188Re solution obtained from the generator (eluate) should be carried out before each synthesis of the radiopharmaceutical. The results of quality control of radiopharmaceuticals synthesized from lyophilized reagent N 1 of domestic and imported production, showed their identity by index «radiochemical purity».</p></trans-abstract><kwd-group xml:lang="ru"><kwd>радиофармацевтические лекарственные препараты</kwd><kwd>рений-188</kwd><kwd>липиодол</kwd><kwd>гепатоцеллюлярная карцинома</kwd><kwd>контроль качества</kwd><kwd>радиохимическая чистота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>radiopharmaceuticals</kwd><kwd>rhenium-188</kwd><kwd>lipiodol</kwd><kwd>hepatocellular carcinoma</kwd><kwd>quality control</kwd><kwd>radiochemical purity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Е. Garin, P. Bourguet. Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd Ed. / Ed. by P.J. Ell and S.S. Gambhir. - Edinburgh: Churchill-Livingstone, 2004. P. 473-483.</mixed-citation><mixed-citation xml:lang="en">Е. Garin, P. Bourguet. Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd Ed. / Ed. by P.J. Ell and S.S. Gambhir. - Edinburgh: Churchill-Livingstone, 2004. P. 473-483.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">K. Bacher, B. Lambert, F. De Vos et al. Patients dosimetry after ¹⁸⁸Re-Lipiodol therapy // Eur. J. Nucl. Med. 2003. V. 30. Suppl. 2. P. 219.</mixed-citation><mixed-citation xml:lang="en">K. Bacher, B. Lambert, F. De Vos et al. Patients dosimetry after ¹⁸⁸Re-Lipiodol therapy // Eur. J. Nucl. Med. 2003. V. 30. Suppl. 2. P. 219.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">B. Lambert, K. Bacher, F. Gemmel et al. ¹⁸⁸Re-Lipiodol for locoregional treatment of hepatocellular carcinoma: a phase I study // Eur. J. Nucl. Med. 2003. V. 30. Suppl. 2. P. 219.</mixed-citation><mixed-citation xml:lang="en">B. Lambert, K. Bacher, F. Gemmel et al. ¹⁸⁸Re-Lipiodol for locoregional treatment of hepatocellular carcinoma: a phase I study // Eur. J. Nucl. Med. 2003. V. 30. Suppl. 2. P. 219.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">P. Bernal, M. Osorio, C. Gutierrez et al. Treatment of liver cancer with Rhenium-188 Lipiodol: Colombian Experience // Eur. J. Nucl. Med. 2002. V. 29. Suppl. 1. P. 180.</mixed-citation><mixed-citation xml:lang="en">P. Bernal, M. Osorio, C. Gutierrez et al. Treatment of liver cancer with Rhenium-188 Lipiodol: Colombian Experience // Eur. J. Nucl. Med. 2002. V. 29. Suppl. 1. P. 180.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">S.L. Chen. Treatment of patients with advanced hepatocellular carcinoma with transarterial ¹⁸⁸Re-lipiodol // Eur. J. Nucl. Med. 2007. V. 34. Suppl. 2. P. 188-189.</mixed-citation><mixed-citation xml:lang="en">S.L. Chen. Treatment of patients with advanced hepatocellular carcinoma with transarterial ¹⁸⁸Re-lipiodol // Eur. J. Nucl. Med. 2007. V. 34. Suppl. 2. P. 188-189.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">K. De Ruyck, A. Vral, B. Lambert et al. Comparison of the cytotoxic effect oа ¹³¹I-lipiodol therapy and ¹⁸⁸Re-lipiodol therapy in hepatocellular cancer patients // Eur. J. Nucl. Med. 2003. V. 30. Suppl. 2. P. 343.</mixed-citation><mixed-citation xml:lang="en">K. De Ruyck, A. Vral, B. Lambert et al. Comparison of the cytotoxic effect oа ¹³¹I-lipiodol therapy and ¹⁸⁸Re-lipiodol therapy in hepatocellular cancer patients // Eur. J. Nucl. Med. 2003. V. 30. Suppl. 2. P. 343.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">K. Nakakuma et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated hepatic artery for hepatic cancer // Nichidoku Iho. 1979. V. 24. P. 675-682.</mixed-citation><mixed-citation xml:lang="en">K. Nakakuma et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated hepatic artery for hepatic cancer // Nichidoku Iho. 1979. V. 24. P. 675-682.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">H. Ohishi et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents // Radiology. 1985. V. 154. P. 25-29.</mixed-citation><mixed-citation xml:lang="en">H. Ohishi et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents // Radiology. 1985. V. 154. P. 25-29.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Патент № 2543342 С2, МПК А61К 103/10. Композиция для лечения рака печени у людей на основе рения-188 и способ получения такой композиции / Н. Нуарэ, Э. Гарин, Н. Лепаръер, В. Ардиссон; патентообладатель Эколь Националь Суперъер Де Хими Де Реннс, Сентр Ожен Маркуа, Университет де Реннс 1 (Франция). - № 2012134282/15, заявл. 18.02.2011; конвенционный приоретет № 1000681, FR от 18.02.2010; опубл. 27.02.2015 Бюл. № 6.</mixed-citation><mixed-citation xml:lang="en">Патент № 2543342 С2, МПК А61К 103/10. Композиция для лечения рака печени у людей на основе рения-188 и способ получения такой композиции / Н. Нуарэ, Э. Гарин, Н. Лепаръер, В. Ардиссон; патентообладатель Эколь Националь Суперъер Де Хими Де Реннс, Сентр Ожен Маркуа, Университет де Реннс 1 (Франция). - № 2012134282/15, заявл. 18.02.2011; конвенционный приоретет № 1000681, FR от 18.02.2010; опубл. 27.02.2015 Бюл. № 6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">N. Lepareur, V. Ardisson, N. Noiret, E. Garin. ¹⁸⁸Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside // Int. J. Mol. Imaging. 2012. Article ID 278306, 9 p., doi:10.1155/2012/278306.</mixed-citation><mixed-citation xml:lang="en">N. Lepareur, V. Ardisson, N. Noiret, E. Garin. ¹⁸⁸Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside // Int. J. Mol. Imaging. 2012. Article ID 278306, 9 p., doi:10.1155/2012/278306.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Патент WO 2011/101436 A1, МПК А61К 51/04 Composition for treating liver cancer in human based on rhenium-188 and method for imaging such composition / N. Noiret, E. Garin, N. Lepareur. - Опубл. 25.08.2011.</mixed-citation><mixed-citation xml:lang="en">Патент WO 2011/101436 A1, МПК А61К 51/04 Composition for treating liver cancer in human based on rhenium-188 and method for imaging such composition / N. Noiret, E. Garin, N. Lepareur. - Опубл. 25.08.2011.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Technical report series N 470: Therapeutic radionuclide generators: ⁹⁰Sr/⁹⁰Y and ¹⁸⁸W/¹⁸⁸Re generators. - Vienna: IAEA, 2009. 249 p.</mixed-citation><mixed-citation xml:lang="en">Technical report series N 470: Therapeutic radionuclide generators: ⁹⁰Sr/⁹⁰Y and ¹⁸⁸W/¹⁸⁸Re generators. - Vienna: IAEA, 2009. 249 p.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">В.Б. Спиваковский. Аналитическая химия олова. - М.: Наука, 1975. 252 с.</mixed-citation><mixed-citation xml:lang="en">В.Б. Спиваковский. Аналитическая химия олова. - М.: Наука, 1975. 252 с.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ф. Умланд, А. Янсен, Д. Тириг, Г. Вюнш. Комплексные соединения в аналитической химии. Теория и практика применения. - М.: Мир, 1975. 536 с.</mixed-citation><mixed-citation xml:lang="en">Ф. Умланд, А. Янсен, Д. Тириг, Г. Вюнш. Комплексные соединения в аналитической химии. Теория и практика применения. - М.: Мир, 1975. 536 с.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">European Pharmacopoeia. 7th ed. 2010.</mixed-citation><mixed-citation xml:lang="en">European Pharmacopoeia. 7th ed. 2010.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
